Meredith Faggen, MD
Hematology & Oncology · S Weymouth, MANPI 1215093968
Payments from drug & device makers
Across 12 payments — averaging $5955.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$51K
- Pfizer$20K
- AstraZeneca$43
- Johnson & Johnson$21
- Gilead$12
- Clovis Oncology, Inc.$3
Across 1 payment — averaging $938.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$938
What the payments were for
- Food & beverage$2126%
- Education$5874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $51,385 |
| Pfizer | 2 | $20,000 |
| AstraZeneca | 1 | $43 |
| Johnson & Johnson | 1 | $21 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $3 |
How this compares
$71,464 in reported general payments places this provider in the 60th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 44 | $550,189 |
| TruqapCapivasertib | 23 | $463,816 |
| PomalystPomalidomide | 20 | $455,401 |
| VerzenioAbemaciclib | 30 | $443,154 |
| OrserduElacestrant Hcl | 17 | $368,622 |
| ZejulaNiraparib Tosylate | 13 | $239,205 |
| CalquenceAcalabrutinib Maleate | 12 | $186,223 |
| Lenalidomide | 12 | $172,548 |
| IbrancePalbociclib | 11 | $170,580 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $132,804 |
| Abiraterone Acetate | 36 | $77,432 |
| EliquisApixaban | 45 | $38,715 |
| XareltoRivaroxaban | 15 | $18,642 |
| Exemestane | 60 | $17,231 |
| Letrozole | 213 | $4,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTruqap, Calquence | $43 | $650,03935 claims |
| PfizerIbrance, Eliquis | $20,000 | $209,29556 claims |
| Johnson & JohnsonXarelto | $21 | $18,64215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in S Weymouth
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Austin KimWorcester$19.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- Jacob SandsBurlington$13.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.